Nov 22, 2021 / 01:30PM GMT
Operator
Hello, and welcome to the Kamada Ltd. Third Quarter 2021 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Bob Yedid with LifeSci Advisors. Please go ahead, Bob.
Robert A. Yedid - LifeSci Advisors, LLC - MD
Thank you, and thank you, all, for joining us. This is Bob Yedid from LifeSci Advisors. Joining me from Kamada are Amir London, Chief Executive Officer; and Chaime Orlev, Chief Financial Officer.
Earlier this morning, Kamada announced a strategic transformational transaction, positioning the company as a global leader in plasma-derived hyperimmune market through the acquisition of a portfolio of 4 FDA-approved plasma-derived commercial products from Saol Therapeutics, a privately held pharmaceutical company, as well as its financial results for the 3 and 9 months ended September 30, 2021. If you have not received these news releases, please go to the Investors page of the company's website.
Before we begin, I'd like to caution that comments made
Q3 2021 Kamada Ltd Earnings Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers